Matt Bogyo
@mbogyo.bsky.social
610 followers 360 following 44 posts
Chemical biologist at Stanford with a love for covalent binding molecules and hydrolases.
Posts Media Videos Starter Packs
mbogyo.bsky.social
Our latest work developing AND-gate probes to image inflammation is out. Great work from Shiyu Chen and collaboration with the group at Merck.

pubs.acs.org/articlesonre...
pubs.acs.org
mbogyo.bsky.social
Thrilled to be speaking at the McCaig International Research Conference on #Osteoarthritis, March 11–13, 2026 in Kananaskis, Alberta 🇨🇦.
Trainee abstract submissions open until Oct 31, 2025!

mccaig.ucalgary.ca/event/intern...

#McCaig2026 #BoneAndJointHealth
Home | MIRC
Advancements in Osteoarthritis: From Discovery to Treatment
mccaig.ucalgary.ca
mbogyo.bsky.social
Having a great time as a senior visiting faculty at Nanyang Technological University in Singapore hosted by Professor Kanyi Pu. Great people and great science.
mbogyo.bsky.social
Macrocyclic Phage Display for Identification of Selective Protease Substrates | Journal of the American Chemical Society pubs.acs.org/doi/full/10....
Macrocyclic Phage Display for Identification of Selective Protease Substrates
Traditional methods for identifying selective protease substrates have primarily relied on synthetic libraries of linear peptides, which offer limited sequence and structural diversity. Here, we present an approach that leverages phage display technology to screen large libraries of chemically modified cyclic peptides, enabling the identification of highly selective substrates for a protease of interest. Our method uses a reactive chemical linker to cyclize peptides on the phage surface, while simultaneously incorporating an affinity tag and a fluorescent reporter. The affinity tag enables capture of the phage library and subsequent release of phages expressing optimal substrates upon incubation with a protease of interest. The addition of a turn-on fluorescent reporter allows direct quantification of cleavage efficiency throughout each selection round. The resulting identified substrates can then be chemically synthesized, optimized and validated using recombinant enzymes and cells. We demonstrate the utility of this approach using Fibroblast Activation Protein α (FAPα) and the related proline-specific protease, dipeptidyl peptidase-4 (DPP4), as targets. Phage selection and subsequent optimization identified substrates with selectivity for each target that have the potential to serve as valuable tools for applications in basic biology and fluorescence image-guided surgery (FIGS). Overall, our strategy provides a rapid and unbiased platform for effectively discovering highly selective, non-natural protease substrates, overcoming key limitations of existing methods.
pubs.acs.org
mbogyo.bsky.social
Our paper outlining a new method for identifying selective protease substrates by phage display is finally out. Nice work from @mbarniolx.bsky.social. pubs.acs.org/doi/full/10....
pubs.acs.org
mbogyo.bsky.social
This work shows that it is possible to find highly potent and selective covalent inhibitors of an enzyme target directly from small fragment libraries containing diverse electrophiles. These new tools can be used to study the function of these bacterial hydrolases which are important for virulence.
mbogyo.bsky.social
The phase IIb results from the multi center trail of our cathepsin probe (VGT-309/abenacianine) are out. The probe met its endpoints and resulted in significant clinical events in 45% of patients. Great work by Vergent Biosciences and Dr. Sunil Singhal (UPenn).

www.vergentbio.com/press-releas...
Vergent Bioscience Presents Phase 2B VISUALIZE Results Demonstrating Abenacianine for Injection (VGT-309) with Intraoperative Molecular Imaging Improved Tumor Visualization During Lung Surgery | Verge...
www.vergentbio.com
Reposted by Matt Bogyo
frutag33.bsky.social
Hello Community!
Are you a postdoc/grad student preparing to launch a faculty search? Do you have a track record of excellence in research, leadership, mentorship & community engagement? Apply to the 2025 Next Generation Faculty Symposium: www.berkeleystanfordnextgensymposium.com! Pls repost! (1/3)
Flyer for the 2025 Next Generation Faculty Symposium (including QR code in top right corner). This symposium highlights the work of exceptional early-career scientists in the broad field of quantitative biological and biomedical sciences, with a track record of excellence in research, leadership, mentorship, and community engagement. These early career scientists are preparing to launch a faculty search. Applications are due May 30th, 2025.
mbogyo.bsky.social
Great visit to Melbourne Uni to give a talk and visit with my former PhD student Laura Edgington-Mitchell and her lab.
mbogyo.bsky.social
Had a great time at #ABPP2025! Great to see so many former lab members and their students and postdocs. Awesome venue and program. Looking forward to ABPP2027 in Leiden and then Ben Cravatt and I will try to bring it to California!
Reposted by Matt Bogyo
verhelstlab.bsky.social
Great keynote of @mbogyo.bsky.social to kick off the second day of #ABPP2025 Impressive progress on probes for image guided surgery and for detection of Staphylococcus aureus.
mbogyo.bsky.social
Great work. Nice to see it out here.
Reposted by Matt Bogyo
donmoyn.bsky.social
Francis Collins led the mapping of the human genome, and chose to do big scientific to benefit the public. He is a a former NIH Director.
He just resigned his position in government. His resignation letter:
www.nytimes.com/2025/03/01/u...
Dr. Collins noted that when he was recruited to the institutes, and through many of the years that followed, “investment in medical research was seen as a high priority and a nonpolitical bipartisan effort — saving countless lives, relieving human suffering and contributing substantially to the U.S. economy.”

“N.I.H. is the largest supporter of biomedical research in the world,” he wrote. “It is the main piston of a biomedical discovery engine that is the envy of the globe. Yet it is not a household name. It should be.”

He went on: “When you hear about patients surviving stage 4 cancer because of immunotherapy, that was based on N.I.H. research over many decades. When you hear about sickle-cell disease being cured because of CRISPR gene editing, that was built on many years of research supported by N.I.H.”